MD Anderson and Replay Announce FDA Clearance of IND Application for First-in-Class TCR NK Cell Therapy for Multiple Myeloma
July 26, 2023
July 26, 2023
HOUSTON, Texas, July 26 (TNSres) -- The University of Texas's MD Anderson Cancer Center issued the following news release on July 24, 2023:
* * *
Phase I study of NY-ESO-1 TCR/IL-15 NK for relapsed or refractory multiple myeloma, first TCR NK clinical study in hematological malignancies, anticipated to commence Q3 2023
* * *
The University of Texas MD Anderson Cancer Center and Replay today announced that the Food & Drug Administration (FDA . . .
* * *
Phase I study of NY-ESO-1 TCR/IL-15 NK for relapsed or refractory multiple myeloma, first TCR NK clinical study in hematological malignancies, anticipated to commence Q3 2023
* * *
The University of Texas MD Anderson Cancer Center and Replay today announced that the Food & Drug Administration (FDA . . .